FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide Phase I/ II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

Ariceum Therapeutics United Kingdom United States of America Germany

225Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonistPhase I/II SANTANA-225 study on track to enrol patients in Q1 2025View original content:https://www.prnewswire.co.uk/news-releases/fda-clears-ariceum-therapeutics-225ac-satoreotide-phase-iii-clinical-study-in-patients-with-small-cell-lung-cancer-or-merkel-cell-carcinoma-302350365.html